123 related articles for article (PubMed ID: 38765328)
1. Utilization Trends of Phosphodiesterase Type-5 Inhibitors for Erectile Dysfunction Between 2019 and 2023 in Tanzania.
Sangeda RZ; Kadinde AW; Masatu CF; Mwalwisi YH; Yahya-Malima KI; Fimbo AM
Cureus; 2024 Apr; 16(4):e58419. PubMed ID: 38765328
[TBL] [Abstract][Full Text] [Related]
2. Trends in Utilization of Emergency Contraceptives in Tanzania: A Retrospective Longitudinal Study From 2018 to 2023.
Kadinde AW; Sangeda RZ; Mwenda L; Yahya-Malima KI; Masatu CF; Mwalwisi YH; Fimbo AM
Cureus; 2024 Apr; 16(4):e57649. PubMed ID: 38707047
[TBL] [Abstract][Full Text] [Related]
3. Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
Yafi FA; Sharlip ID; Becher EF
Sex Med Rev; 2018 Apr; 6(2):242-252. PubMed ID: 28923561
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
5. Safety profile and signal detection of phosphodiesterase type 5 inhibitors for erectile dysfunction: a Food and Drug Administration Adverse Event Reporting System analysis.
Shin YE; Rojanasarot S; Hincapie AL; Guo JJ
Sex Med; 2023 Oct; 11(5):qfad059. PubMed ID: 38034088
[TBL] [Abstract][Full Text] [Related]
6. PDE5is-naïve versus non-naïve patients at first investigation for erectile dysfunction-findings from a long-term, real-life cross-sectional study.
Cilio S; Capogrosso P; Pozzi E; Belladelli F; Corsini C; Raffo M; Candela L; Fallara G; Boeri L; d'Arma A; Imbimbo C; Mirone V; Montorsi F; Salonia A
Andrology; 2024 Apr; ():. PubMed ID: 38588296
[TBL] [Abstract][Full Text] [Related]
7. Oral phosphodiesterase type 5 inhibitors and male reproductive potential: an overview.
Mostafa T; Alghobary M; Hanafy NS; Abosief A
Sex Med Rev; 2023 Jun; 11(3):240-252. PubMed ID: 36990971
[TBL] [Abstract][Full Text] [Related]
8. Low-Intensity Extracorporeal Shockwave Therapy Can Improve Erectile Function in Patients Who Failed to Respond to Phosphodiesterase Type 5 Inhibitors.
Tsai CC; Wang CJ; Lee YC; Kuo YT; Lin HH; Li CC; Wu WJ; Liu CC
Am J Mens Health; 2017 Nov; 11(6):1781-1790. PubMed ID: 28884638
[TBL] [Abstract][Full Text] [Related]
9. Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction.
von Büren M; Rodler S; Wiesenhütter I; Schröder F; Buchner A; Stief C; Gratzke C; Wülfing C; von Büren J
Eur Urol Focus; 2022 May; 8(3):794-802. PubMed ID: 34006491
[TBL] [Abstract][Full Text] [Related]
10. The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Ventimiglia E; Capogrosso P; Montorsi F; Salonia A
Expert Opin Drug Saf; 2016; 15(2):141-52. PubMed ID: 26752541
[TBL] [Abstract][Full Text] [Related]
11. Effect of Genetic Polymorphism on the Response to PDE5 Inhibitors in Patients With Erectile Dysfunction: A Systematic Review and a Critical Appraisal.
Mostafa T; Hassan A; Alghobary MF; Abdelrahman SH
Sex Med Rev; 2020 Oct; 8(4):573-585. PubMed ID: 32636154
[TBL] [Abstract][Full Text] [Related]
12. National Antibiotics Utilization Trends for Human Use in Tanzania from 2010 to 2016 Inferred from Tanzania Medicines and Medical Devices Authority Importation Data.
Sangeda RZ; Saburi HA; Masatu FC; Aiko BG; Mboya EA; Mkumbwa S; Bitegeko A; Mwalwisi YH; Nkiligi EA; Chambuso M; Sillo HB; Fimbo AM; Horumpende PG
Antibiotics (Basel); 2021 Oct; 10(10):. PubMed ID: 34680829
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
[TBL] [Abstract][Full Text] [Related]
14. Current management strategy of treating patients with erectile dysfunction after radical prostatectomy: a systematic review and meta-analysis.
Feng D; Tang C; Liu S; Yang Y; Han P; Wei W
Int J Impot Res; 2022 Jan; 34(1):18-36. PubMed ID: 33099581
[TBL] [Abstract][Full Text] [Related]
15. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function.
Basal S; Wambi C; Acikel C; Gupta M; Badani K
BJU Int; 2013 Apr; 111(4):658-65. PubMed ID: 23186312
[TBL] [Abstract][Full Text] [Related]
16. [Sexual life quality of spinal cord-injured men receiving pharmacological treatment for erectile dysfunction and their partners].
Sánchez-Ramos A; Galán-Ruano A; Vargas-Baquero E; Mas M
Rev Int Androl; 2018; 16(3):95-101. PubMed ID: 30300136
[TBL] [Abstract][Full Text] [Related]
17. How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors.
Jannini EA; DeRogatis LR; Chung E; Brock GB
J Sex Med; 2012 Jan; 9(1):26-33. PubMed ID: 22221307
[TBL] [Abstract][Full Text] [Related]
18. Comparison of efficacy and safety of daily oral L-arginine and PDE5Is alone or combination in treating erectile dysfunction: A systematic review and meta-analysis of randomised controlled trials.
Xu Z; Liu C; Liu S; Zhou Z
Andrologia; 2021 May; 53(4):e14007. PubMed ID: 33587304
[TBL] [Abstract][Full Text] [Related]
19. Counterfeit phosphodiesterase type 5 inhibitors pose significant safety risks.
Jackson G; Arver S; Banks I; Stecher VJ
Int J Clin Pract; 2010 Mar; 64(4):497-504. PubMed ID: 20088883
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
